FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

					_														
1. Name ar	2. Issuer Name and Ticker or Trading Symbol Arcutis Biotherapeutics, Inc. [ARQT]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable)									
Welgus Howard G.						medis Bromerapeanes, me. [meq 1]								1	Direc	tor		10% Ov	vner
											Office	er (give title		Other (s	specify				
(Last)	3. Date of Earliest Transaction (Month/Day/Year) 01/02/2025										Delov	v)		below)					
C/O ARG																			
3027 TOWNSGATE ROAD, SUITE 300																			
						4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street) WESTLAKE														1	Form	filed by One	e Rep	orting Perso	on
VILLAGE CA 913			136	1											Form filed by More than One Reporting				
														Perso	on				
(City)	(State) (Zip)																		
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Yea							n Date,	Date, Tr			4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 an			d 5) Sec Ben		ount of ities icially	6. Ownership Form: Direct (D) or	7. Nature of Indirect Beneficial	
						(Month/Day/Year)		r) 8)	8)		1				Owned Following Reported Transaction(s) (Instr. 3 and 4)		Indir (Inst		Ownership (Instr. 4)
							C		ode	v A	mount	(A) or (D)	Price						
Common Stock 01/02/2025								S		10,000(1)	D	\$14.67	514.6714 ⁽²⁾		151,944		D		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
				(e.g., pu	ts, c	alls, v	varra	ınts,	op	tions,	convertil	ble se	curities	s) 					
Derivative Conversion Date Security or Exercise (Month/Day/Year)			Exe if a	3A. Deemed Execution Date, if any (Month/Day/Year)		4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		Date Exe piration I onth/Day		Amo Secu Unde Deriv	tle and unt of urities erlying vative urity (Instr. d 4)	Der Sec	rice of vative urity tr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	e s lly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Dat Exe	te ercisable	Expiration Date	Title	Amount or Number of Shares						

Explanation of Responses:

- 1. The transaction reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on March 5, 2024, by the Reporting Person, with a plan end date of May 30, 2025.
- 2. The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from \$14.16 to \$15.11, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Remarks:

/s/ David Topper, as Attorney-01/06/2025 in-Fact for Howard G. Welgus

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.